8-K
Stereotaxis, Inc. (STXS)
View as plain text
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(D) of the Securities Exchange Act Of 1934
Date of report (Date of earliest event reported): May 10, 2021
STEREOTAXIS,
INC.
(Exact Name of Registrant as Specified in Its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
| 001-36159 | 94-3120386 |
|---|---|
| (Commission<br> File Number) | (IRS<br> Employer Identification No.) |
| 4320 Forest Park Avenue, Suite 100, St. Louis, Missouri | 63108 |
| --- | --- |
| (Address<br> of Principal Executive Offices) | (Zip<br> Code) |
(314)678-6100
(Registrant’s Telephone Number, Including Area Code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written<br> communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting<br> material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement<br> communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement<br> communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securitiesregistered pursuant to Section 12(b) of the Act: [ ]
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Common<br> Stock, par value $0.001 per share | STXS | NYSE<br> American LLC |
Item2.02 Results of Operations and Financial Condition
On May 10, 2021, Stereotaxis, Inc. (the “Company”) issued a press release (the “Earnings Press Release”) setting forth its financial results for the 2021 first quarter. A copy of the Earnings Press Release is being filed as Exhibit 99.1 hereto, and the statements contained therein are incorporated by reference herein.
Forward-Looking Statements and Additional Information
Statements are made herein or incorporated herein that are “forward-looking statements” as defined by the Securities and Exchange Commission (the “SEC”). All statements, other than statements of historical fact, included or incorporated herein that address activities, events or developments that the Company expects, believes or anticipates will or may occur in the future are forward-looking statements. These statements are not guarantees of future events or the Company’s future performance and are subject to risks, uncertainties and other important factors that could cause events or the Company’s actual performance or achievements to be materially different than those projected by the Company. For a full discussion of these risks, uncertainties and factors, the Company encourages you to read its documents on file with the SEC. Except as required by law, the Company does not intend to update or revise its forward-looking statements, whether as a result of new information, future events or otherwise.
In accordance with General Instruction B.2. of Form 8-K, the information contained in Item 2.02 and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits
| (d) | Exhibits. |
|---|---|
| 99.1 | Stereotaxis, Inc. Earnings Press Release dated May 10, 2021. |
| --- | --- |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| STEREOTAXIS, INC. | ||
|---|---|---|
| Date:<br> May 10, 2021 | By: | /s/ Kimberly R. Peery |
| Name: | Kimberly<br> R. Peery | |
| Title: | Chief<br> Financial Officer |
Exhibit99.1
StereotaxisReports 2021 First Quarter Financial Results
ST.LOUIS, MO, May 10, 2021 (GLOBE NEWSWIRE) – Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the first quarter ended March 31, 2021.
“The highlight of the first quarter is Stereotaxis’ return to robust double digit revenue growth with 50% topline growth,” said David Fischel, Chairman and CEO. “The results reflect the initial impact of the first wave of our strategic innovation plan.”
“During the quarter two robotic systems were shipped to hospitals establishing new robotic electrophysiology practices, triggering partial revenue recognition of those systems. Since the quarterly results two months ago, we received an additional purchase order for a robotic system in the United States.”
“We continue to advance a robust innovation pipeline. Our proprietary robotically-navigated magnetic ablation catheter is advancing methodically through required manufacturing and testing processes. We anticipate submitting for regulatory approval in Europe in September and for initiating a US pivotal trial shortly thereafter. At the end of the year we expect to showcase an additional set of innovations that will accelerate adoption of our robotic technology in electrophysiology and beyond. We are confident in the positive impact these innovations will have on patients, physicians, providers, and on Stereotaxis’ financial and strategic foundation.”
“Our commercial and technological progress is being accomplished while remaining prudent with shareholder capital. We continue to invest in the team, infrastructure and projects that are critical for both near and long-term success, and are proud that we are able to do so while maintaining financial discipline.”
2021First Quarter Financial Results
Revenue for the first quarter of 2021 totaled $8.6 million, a 50% increase from $5.8 million in the prior year first quarter. System revenue of $2.6 million reflects initial revenue recognition on the delivery of a Genesis RMN^®^ system to Europe and a Niobe^®^system to China. Recurring revenue for the quarter was $5.8 million, compared to $5.5 million in the prior year first quarter.
Gross margin for the first quarter of 2021 was 70% of revenue, with system gross margin of 45% and recurring revenue gross margin of 84%. Operating expenses in the quarter were $7.5 million including $1.4 million in non-cash stock compensation expense. Increased non-cash stock compensation expense is a reflection of an increased stock price and the previously announced CEO Performance Stock Plan. Excluding stock compensation expense, adjusted operating expenses in the current quarter were $6.2 million consistent with the prior year adjusted operating expenses of $6.1 million.
Operating loss and net loss for the first quarter of 2021 were ($1.5) million, compared to ($2.1) million and ($2.0) million respectively in the previous year. Adjusted operating loss and adjusted net loss for the quarter, excluding non-cash stock compensation expense, were ($0.2) million compared to ($1.3) million in the prior year. Negative free cash flow for the first quarter was ($0.3) million, compared to ($2.2) million in the prior year first quarter.
CashBalance and Liquidity
At March 31, 2021, Stereotaxis had cash and cash equivalents, including restricted cash and compensating balances, of $44.1 million.
ForwardLooking Expectations
Stereotaxis continues to expect robust double-digit revenue growth in 2021, with robotic system revenue of $10-$20 million. Stereotaxis’ balance sheet allows it to reach profitability without the need for additional financings.
ConferenceCall and Webcast
Stereotaxis will host a conference call and webcast today, May 10, 2021, at 10:00 a.m. Eastern Time. To access the conference call, dial 1-800-367-2403 (US and Canada) or 1-334-777-6978 (International) and give the participant pass code 6657929. Participants are asked to call 5-10 minutes prior to the start time. To access the live and replay webcast, please visit the investor relations section of the Stereotaxis website at www.Stereotaxis.com.
AboutStereotaxis
Stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, Japan, Canada, China, and elsewhere. For more information, please visit www.Stereotaxis.com.
Thispress release includes statements that may constitute “forward-looking” statements, usually containing the words “believe”,“estimate”, “project”, “expect” or similar expressions. Forward-looking statements inherently involverisks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that wouldcause or contribute to such differences include, but are not limited to, the Company’s ability to continue to manage expenses andcash burn rate at sustainable levels, continued acceptance of the Company’s products in the marketplace, the effect of global economicconditions on the ability and willingness of customers to purchase its systems and the timing of such purchases, competitive factors,changes resulting from healthcare policy in the United States, including changes in government reimbursement of procedures, dependenceupon third-party vendors, timing of regulatory approvals, the impact of the recent coronavirus (COVID-19) pandemic and our response toit, and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By makingthese forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after thedate of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitmentsin any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that areoutside of the Company’s control. In addition, these orders and commitments may be revised, modified, delayed or canceled, eitherby their express terms, as a result of negotiations, or by overall project changes or delays.
CompanyContacts:
David L. Fischel
Chairman and Chief Executive Officer
Kimberly R. Peery
Chief Financial Officer
314-678-6100
investors@stereotaxis.com
STEREOTAXIS, INC.
STATEMENTS OF OPERATIONS
(Unaudited)
| Three Months Ended March 31, | ||||||
|---|---|---|---|---|---|---|
| 2021 | 2020 | |||||
| Revenue: | ||||||
| Systems | $ | 2,602,512 | $ | - | ||
| Disposables, service and accessories | 5,773,516 | 5,509,711 | ||||
| Sublease | 246,530 | 246,530 | ||||
| Total revenue | 8,622,558 | 5,756,241 | ||||
| Cost of revenue: | ||||||
| Systems | 1,435,535 | 65,022 | ||||
| Disposables, service and accessories | 924,618 | 639,863 | ||||
| Sublease | 246,530 | 246,530 | ||||
| Total cost of revenue | 2,606,683 | 951,415 | ||||
| Gross margin | 6,015,875 | 4,804,826 | ||||
| Operating expenses: | ||||||
| Research and development | 2,367,041 | 2,109,170 | ||||
| Sales and marketing | 2,947,216 | 2,915,424 | ||||
| General and administrative | 2,229,739 | 1,832,726 | ||||
| Total operating expenses | 7,543,996 | 6,857,320 | ||||
| Operating loss | (1,528,121 | ) | (2,052,494 | ) | ||
| Interest income (expense), net | (4,276 | ) | 80,963 | |||
| Net loss | $ | (1,532,397 | ) | $ | (1,971,531 | ) |
| Cumulative dividend on convertible preferred stock | (332,551 | ) | (343,723 | ) | ||
| Net loss attributable to common stockholders | $ | (1,864,948 | ) | $ | (2,315,254 | ) |
| Net loss per share attributed to common stockholder: | ||||||
| Basic | $ | (0.02 | ) | $ | (0.03 | ) |
| Diluted | $ | (0.02 | ) | $ | (0.03 | ) |
| Weighted average number of common shares and equivalents: | ||||||
| Basic | 75,175,412 | 69,870,040 | ||||
| Diluted | 75,175,412 | 69,870,040 |
STEREOTAXIS, INC.
BALANCE SHEETS
| December 31,<br><br> <br>2020 | |||||
|---|---|---|---|---|---|
| Assets | |||||
| Current assets: | |||||
| Cash and cash equivalents | 42,452,713 | $ | 43,939,512 | ||
| Restricted cash - current | 1,336,000 | - | |||
| Compensating cash arrangement | 250,919 | 250,620 | |||
| Accounts receivable, net of allowance of 122,570 and 123,614 at 2021 and 2020, respectively | 7,290,762 | 3,515,136 | |||
| Inventories, net | 3,536,300 | 3,295,457 | |||
| Prepaid expenses and other current assets | 1,674,554 | 1,716,014 | |||
| Total current assets | 56,541,248 | 52,716,739 | |||
| Property and equipment, net | 202,504 | 195,129 | |||
| Restricted cash | 93,331 | - | |||
| Operating lease right-of-use assets | 1,695,664 | 2,235,442 | |||
| Other assets | 284,946 | 308,515 | |||
| Total assets | 58,817,693 | $ | 55,455,825 | ||
| Liabilities and stockholders’ equity | |||||
| Current liabilities: | |||||
| Short-term debt | 1,914,692 | $ | 1,185,058 | ||
| Accounts payable | 2,270,432 | 1,608,636 | |||
| Accrued liabilities | 2,578,298 | 3,209,235 | |||
| Deferred revenue | 8,188,296 | 5,282,770 | |||
| Current portion of operating lease liabilities | 1,734,699 | 2,287,487 | |||
| Total current liabilities | 16,686,417 | 13,573,186 | |||
| Long-term debt | 243,617 | 973,252 | |||
| Long-term deferred revenue | 1,328,272 | 548,915 | |||
| Other liabilities | 210,096 | 131,231 | |||
| Total liabilities | 18,468,402 | 15,226,584 | |||
| Series A - Convertible preferred stock: | |||||
| Convertible preferred stock, Series A, par value 0.001; 22,408 and 22,513 shares outstanding at 2021 and 2020, respectively | 5,578,437 | 5,605,323 | |||
| Stockholders’ equity: | |||||
| Convertible preferred stock, Series B, par value 0.001; 10,000,000 shares authorized, 5,610,121 shares outstanding at 2021 and 2020 | 5,610 | 5,610 | |||
| Common stock, par value 0.001; 300,000,000 shares authorized, 74,089,659 and 73,694,203 shares issued at 2021 and 2020, respectively | 74,090 | 73,694 | |||
| Additional paid-in capital | 524,388,783 | 522,709,846 | |||
| Treasury stock, 4,015 shares at 2021 and 2020 | (205,999 | ) | (205,999 | ) | |
| Accumulated deficit | (489,491,630 | ) | (487,959,233 | ) | |
| Total stockholders’ equity | 34,770,854 | 34,623,918 | |||
| Total liabilities and stockholders’ equity | 58,817,693 | $ | 55,455,825 |
All values are in US Dollars.